You are here
Planet Biotechnology Incorporated
UEI: KTJKPBE2H5H3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Amount: $1,000,000.00Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sens ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
Amount: $298,634.00Our overall goal is to reduce to practice an innovative new method for empirically identifying the optimal codon usage for any gene where the intent is to maximize protein accumulation, in either hete ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Recombinant Fc fusions for treatment of uropathogenic E. coli
Amount: $486,870.00Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases ...
STTRPhase I2020Department of Health and Human Services National Institutes of Health -
An immunotherapeutic to prevent gonorrhea
Amount: $1,727,108.00Antimicrobial resistance is a major public health problem worldwide. Neisseria gonorrhoeae (Ng), the causative agent of the sexually transmitted infection gonorrhea, has become multidrug-resistant and ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
Amount: $444,684.00Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sens ...
STTRPhase I2020Department of Health and Human Services National Institutes of Health -
An immunotherapeutic to prevent gonorrhea
Amount: $300,000.00Antimicrobial resistance is a major public health problem worldwideNeisseria gonorrhoeaeNgthe causative agent of the sexually transmitted infection gonorrheahas become multidrug resistant and has achi ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
An immunoadhesin therapy for glioblastoma targeting CD97
Amount: $263,999.00Effective treatment of glioblastomaGBMthe most common and most lethal human brain tumorrepresents one of the most formidable challenges in oncologyDespite the use of surgeryradiation therapy and chemo ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
A mucosally targeted MERS CoV vaccine produced in plants
Amount: $236,488.00DESCRIPTION provided by applicant Middle East Respiratory Syndrome MERS coronavirus MERS CoV causes severe acute respiratory illness with a high fatality rate among reported cases MERS was fi ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
A novel anti gonorrhea immunotherapeutic
Amount: $242,093.00Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
A MERS-CoV Receptor Decoy
Amount: $1,575,242.00DESCRIPTION provided by applicant Middle East respiratory syndrome coronavirus MERS CoV is a newly emerging human health threat with a case fatality rate MERS CoV uses dipeptidyl peptidase ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health
